Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET, OTCQB:MSSTF, FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to explain how the company has been able confirm the psychedelic effect of its novel compounds with greater accuracy.
Lanthier and Araujo say in partnership with InterVivo Solutions, Mindset has trained rats to discriminate psilocybin effects from saline via oral and subcutaneous dosing, which to the company’s knowledge is a first in the psychedelics field of research.